For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $ ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning, and welcome to Johnson & ...

investors cite weak medical device sales Depression drug Spravato expected to generate $3 billion-3.5 billion in annual sales by 2028 April 15 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab ...

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...

Bryan Johnson, the anti-aging influencer, halted his Rapamycin regimen after five years due to adverse side effects like ...

The chief executive of Johnson & Johnson has warned that potential ... Joe Wolk said the administration’s investigation into drug imports, widely seen as a first step toward imposing levies ...